Skip to main content
Premium Trial:

Request an Annual Quote

Celera s Revenues Down, Losses Narrowed in Q4; Will Sell Rockville Facility

NEW YORK, July 28 (GenomeWeb News) - Celera Genomics today reported narrowed losses and a drop in revenues in the fourth quarter of its fiscal year 2004.

 

It also said that it was planning to sell its facility in Rockville, Md.

 

Celera, a unit of Applera, reported a net loss of $5.8 million for Q4 2004 as compared to $19.4 million in Q4 2003. The company said the Q4 results included a $24.8 million pre-tax gain associated with the  sale of its investment in Discovery Partners International, as well as an $18.1 million non-cash pre-tax charge representing the estimated loss on the planned Rockvillesale.

 

The $18.1 million write-off is due to losses Celera expects to incur after selling the two-building facility in Rockville. Robert Bennett, a spokesman for the company, said Celera bought the property at the height of the market and would sell it at a loss.

 

He also said the company would lease the facility from its new owners, and retain the proteomics and bioinformatics divisions that work there.

 

Celera's revenues decreased to $12.4 million in Q4 2004, from $21.5 million in the same quarter last year. The company attributed the losses primarily to continuing expiration of online and information business customer agreements.

 

The company saw a slight rise in its R&D spending in Q4 2004, to $29.4 million, from $28.5 million in Q4 2003. Celera said the rise was primarily to support preclinical development activities and the hiring of additional therapeutic R&D personnel.

 

As of June 30, Celera's cash and short-term investments totaled approximately $746 million.

 

Julia Karowcontributed to this report.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.